Novavax, Inc.
9.70USD
-0.2900 (-2.90%)
Not enough data yet
A reading needs 5 members, each at least 14 days old with a track record on this site (simulated portfolios and calls), who shared a take in the last 30 days; 2 of them need a strong record.
Sign in to share your take on NVAX.
Revenue
| (USD) | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|
| FY | 2.0B | 983.7M | 682.2M | 1.1B | 389.3M | 290.3M |
| Q1 | 704.0M | 81.0M | 93.9M | 666.7M | 139.5M | — |
| Q2 | 185.9M | 424.4M | 415.5M | 239.2M | 56.7M | — |
| Q3 | 734.6M | 187.0M | 84.5M | 70.4M | 74.6M | — |
| Q4 | 357.4M* | 291.3M* | 88.3M* | 147.1M* | 105.6M | — |
Revenue
| (USD) | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|
| FY | -8.42 | -5.41 | -1.23 | 2.58 | -.520 | -.083 |
| Q1 | 2.56 | -3.41 | -1.05 | 2.93 | -.060 | — |
| Q2 | -6.53 | .580 | .990 | .620 | -.320 | — |
| Q3 | -2.15 | -1.26 | -.760 | -1.25 | -.220 | — |
| Q4 | -2.33* |
Fiscal period: Reported, Estimated. Reported figures: SEC filings (EDGAR). Estimates are sell-side consensus for periods that have not reported. Cells marked * were synthesized from the annual filing less the year-to-date figures, because the quarter was not filed on its own. Earnings per share are restated onto today's share basis, so a period before a stock split is comparable with the ones after it.
Revenue to net income
| -1.77* |
| -.532* |
| .101* |
| -.049 |
| — |
Debt level and coverage